Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in advanced hepatocellular carcinoma with impaired liver function
NCT01932385Phase 3Completed
- Sponsor
- Affiliated Qingdao Central Hospital of Qingdao University
- Start
- Aug 2013
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by Affiliated Qingdao Central Hospital of Qingdao University. Started Aug 2013; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01932385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01932385.